DARZALEX® dosing

Share

Sirius_Mobile_Trial_Page_Badge

DARZALEX® (daratumumab)

Dose DARZALEX® at 16 mg/kg of actual body weight as an intravenous (IV) infusion1

DARZALEX® dosing frequency decreases throughout the course of therapy1

Want a PDF of the DARZALEX® dosing schedule?

Looking for a comprehensive guide with DARZALEX® dosing & administration?

  • Administer DARZALEX® only as an IV infusion after dilution1
  • DARZALEX® should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur1
  • If a planned dose of DARZALEX® is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval1

Interference with Serological Testing

  • Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test)
  • Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion
  • Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type is not impacted
  • Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX®
  • Type and screen patients prior to starting DARZALEX®

Find out more about interference with serological testing for patients being treated with DARZALEX®

Provide this document to patients to let healthcare professionals know that the patient is being treated with DARZALEX®

 

Interference with determination of complete response1

  • Daratumumab is a human immunoglobulin G (IgG) kappa mAb that can be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays, which can impact the determination of a CR and of disease progression in some patients with IgG kappa myeloma protein